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High-intensity focused ultrasound (HIFU) is a rapidly developing, non-invasive technique for local treatment of solid
tumors that produce coagulative tumor necrosis. This study is aimed to investigate the feasibility of proton
magnetic resonance spectroscopy (MRS) on early assessing treatment of HIFU ablation in rabbit with VX2 liver
tumor. HIFU ablation was performed on normal liver and VX2 tumor in rabbit, and MRS was performed on normal
liver and VX2 tumor before and 2 days after 100% HIFU ablation or 80% ablation in tumor volume. Choline (Cho)
and choline/lipid (Cho/Lip) ratios between complete and partial HIFU ablation of tumor were compared. Tissues
were harvested and sequentially sliced to confirm the necrosis. In normal liver, the Cho value liver was not
obviously changed after HIFU (P N .05), but the Cho/Lip ratio was decreased (P b .05). Cho in liver VX2 tumor was
much higher than that in normal liver (P b .001). Cho and Cho/Lip ratio were significantly decreased in tumor after
complete HIFU ablation and partial HIFU ablation, and the Cho value in complete HIFU tumor ablation did not show
any difference from that in normal liver after HIFU (P N .05); however, the Cho value in partial ablation was still
higher than that in normal liver before or in tumor after complete HIFU treatment due to the residual part of tumors,
and Cho/Lip ratio is lower than that in complete HIFU treatment (P b .001). The changes in MRS parameters were
consistent with histopathologic changes of the tumor tissues after treatment. MRS could differentiate the
complete tumor necrosis from residual tumor tissue, when combined with magnetic resonance imaging. We
conclude that MRS may be applied as an important, non-invasive biomarker for monitoring the thoroughness of
HIFU ablation.
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High-intensity focused ultrasound (HIFU) is a rapidly developing,
non-invasive technique for local treatment of solid malignancies that
can produce coagulative tumor necrosis and destroy tumor blood
vessels at a precise focal point, without harming overlying and
adjacent structures even within the path of the beam [1,2].
Recent clinical trials showed favorable outcomes ofHIFU ablation in
liver cancer, which can be used as a viable, non-invasive cancer ablation
approach, especially for intermediate to advanced stage liver cancer [3].
The success of HIFU treatment relies on complete coagulative tumor
necrosis after HIFU ablation. The verification of completeness of
coagulative tumor necrosis immediately or early after HIFU ablation is
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techniques. Therefore, the utility of appropriate imaging method,
which can accurately and timely evaluate the completeness of tumor
necrosis after HIFU treatment, will have very important clinical
significance [3,4]. On timely detection, any residual tumor may regain
the chance of eradication through a complementary treatment during
the initial or early after HIFU ablation.
Magnetic resonance spectroscopy (MRS) can qualify intracellular
biochemical and metabolite concentration in vivo as a non-invasive
means for the characterization of tissue and pathophysiological
changes, which is used to aid in diagnosis in tumors as well as to
monitor the cancer treatment response. Clinical studies also showed
the value of MRS for the differentiation of recurrent or residual brain
tumor activity from surrounding healthy tissue and necrotic tumor
processes [4,5]. MRS has been used to evaluate the focal hepatic
lesions and the early stage metabolic changes of hepatocellular
carcinoma after transcatheter arterial chemoembolization [6]. There-
fore, MRS may have the potential to evaluate coagulative tumor
necrosis in vivo after HIFU ablation. The aim of this study is to
investigate the possibility of MRS as a non-invasive technique to
differentiate the complete coagulative tumor necrosis from residual
tumor tissue. Herein, we conducted the study to examine MRS
change in normal liver after HIFU ablation and the differences of
MRS in distinct extent of coagulative necrosis of HIFU-ablated VX2
liver tumor followed by subsequent histologic documentation.
We found that choline (Cho) compounds and choline/lipid (Cho/
Lip) ratio in liver VX2 tumor were increased and decreased to the
level of ablated normal liver after tumor HIFU ablation. The changes
of metabolites in tumor tissue observed in MRS were consistent with
histopathologic changes. The findings suggest that MRS could
differentiate the complete from residual tumor tissue and may be
applied as an important, non-invasive marker for monitoring the
thoroughness of HIFU ablation.
Materials and Methods
Animals
The animal experiments were in compliance with national and
international regulations and approved by the Ethical Committee of
Chongqing Medical University. Thirty-three New Zealand white
rabbits (weight, 2.0–3.0 kg) were used in the study, which were
purchased from the Animal Experimental Center of Chongqing
Medical University (Chongqing, China). The VX2 cell line was
derived from the rabbit VX2 squamous carcinoma, which was provided
by the Institute of Ultrasonic Engineering in Medicine, Department of
Biomedical Engineering, Chongqing Medical University.
Establishment of Tumor Model
Rabbits were inoculated subcutaneously with liver VX2 cells and
showed tumor growth. When the size of the tumors reached 7 to 8
mm3 in volume, the tumors were harvested, washed with normal
saline, and then subdivided into small pieces of tissues of
approximately 1 mm3. The abdomen of the rabbit was routinely
opened by median incision and the left or middle lobe of the liver was
pricked to form a hole approximately 1 to 2 mm deep with
ophthalmologic forceps. One piece of subdivided tissue was
implanted into the hole. Bleeding points were stopped with gauze.
The abdominal wall was sutured. The rabbits were administrated
penicillin for 3 days after operation to prevent infection. Thirty-threerabbits were randomly divided into two groups, non-tumor group
(normal control; n = 12) and tumor group (n = 21). After the
establishment of rabbit liver tumor model, rabbits bearing VX2
tumors were randomly divided into two subgroups: tumor complete
ablation (100% ablation of the tumor volume) and tumor partial
ablation (80% ablation of the tumor volume) [7–9].
HIFU Treatment
Abdominal skin of each animal was shaved with 8% sodium sulfide
24 hours before the experiments. A model JC200 High-Intensity
Focused Ultrasound Tumor Therapeutic System (Chongqing Haifu
(HIFU) Technology Co Ltd, Chongqing, China) was used to ablate the
whole mass of liver tumor in the complete ablation group and ablate
80% of tumor in volume in the partial ablation group. The strategy of
treatment is HIFU ablation from “lines” to “slices”, from “slices” to
“volume”, and fromdeep to shallow. B-mode ultrasonography (US) was
used to target and monitor the whole therapeutic procedure HIFU
treatment with parameters including interlamellar spacing of 3 mm,
interline spacing of 5 mm, scanning speed of 3 mm/s, frequency set at
1.0 MHz, and acoustic power fixed at 180 W. The HIFU ablation
procedure was in compliance with the guidance of the National
Standard of China and has been described in detail previously [9].
Magnetic Resonance Imaging and MRS
Magnetic resonance imaging (MRI) was performed before and
immediately after ablation using an MRI scanner (GE Signa Excite II
1.5 T) with an eight-channel cardiac phased array coil. The rabbits
were subjected to the following MRI protocols: axial T1-weighted
spin echo [repetition time (TR) of 170ms, an echo time (TE) of 6.9ms,
a slice thickness of 3.0 mm, Field of view (FOV) = 180 × 180 mm,
matrix = 256 × 192, and number of excitation = 3]; axial T2-weighted
fast spin echo (TR = 3000ms, TE = 85ms, a slice thickness of 3.0 mm,
1.0-mm spacing, FOV = 180 × 180 mm, matrix = 256 × 192, and
number of excitation = 6); MRS single voxel was performed by using
point resolved spectroscopy sequences (TR = 3000 ms, TE = 35 ms,
FOV = 240 × 240mm, matrix = 1 × 1, and number of excitation = 8).
MRS volume of interest was placed to cover the whole lesion based
on lesion volume on T1WI and T2WI, and then outer volume
saturation bands were placed around the volume of interest to avoid
signal intensity contaminations. Peak assignments were given as
follows: Cho at 3.22 ppm and lipids (Lip) at 1.3 ppm. The areas
under the peaks are proportional to the metabolite concentrations,
and Cho/Lip ratio was calculated.
Data Processing
After the acquisition process, raw data were post-processed with
Saker software (GE) including the following steps: apodization,
zero-filling, phase correction, baseline correction and the measure-
ment of the area under the peak. The abscissa represents the
magnitude of the chemical shift, and the magnetic resonance
frequencies are expressed in “parts per million”; the ordinate
represents the signal intensity of metabolites. The Cho-containing
compound signal is detected as a single peak observed at 3.2 ppm;
lipid signal is detected as a single peak observed at 1.3 ppm. The area
under the peak was measured, and the Cho/Lip ratio was calculated.
Histology
Three liver samples of each group were collected before HIFU
ablation as histologic studies, and other liver samples were collected
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conserved in 10% formalin, and 5-μm-thick sequential sections were
prepared for hematoxylin and eosin (H&E) staining to evaluate the
basic histomorphology of the specimens.
Data Analysis
All data are expressed as the mean ± SD. Differences of the same
group before and after HIFU ablation were evaluated by t test. The
comparisons of the area under the Cho peak, area, and Cho/Lip ratio
between groups were performed using a one-way analysis of variance
followed by Fisher least significant difference post hoc test; P b .05
was considered as a statistically significant difference. Data were
analyzed with the SPSS 13.0 statistical software package.
Results
Cho/Lip Ratio of Normal Liver Increases after Complete
HIFU Ablation
Normal livers show normal T1-weighted images (T1WI) and
T2-weighted images (T2WI) without mass in the left lobe of the liver
(Figure 1,A andB).Histologic staining shows a normal liver architecture
before HIFU (Figure 1D). Cho peak appeared at 3.2 ppm and Lip peak
appeared at 1.3 ppm; the measured Cho/Lip ratio is 0.03 ± 0.00
(Figure 3). After complete HIFU ablation of normal liver, a lower
intensity signal appeared on T1WI in the left lobe of normal liver, and
T2WI shows a slightly high intensity signal (Figure 1, E and F ). The
MRS after HIFU shows a similar pattern to that before HIFU, and the
Cho resonance is at 3.2 ppm with no significant changes in amplitude;
however, the lipid resonance at 1.3 ppm increased, and Cho/Lip ratio
after HIFU decreased to 0.02 ± 0.00 (Figures 1G and 3). The
H&E-stained section shows lysed membranes, poorly delineated cells,
pycnotic nuclei, nuclear fragmentation, and heavy staining of hepatocyte
cytoplasm after HIFU ablation (Figure 1H ).Figure 1. The MRI and MRS of normal liver before and after HIFU abla
liver. (B) T2WI of normal liver shows no mass in the left lobe of the live
ppm and Lip peak appeared at 1.3 ppm; the measured Cho/Lip rati
architecture before HIFU. (E) On T1WI after HIFU ablation, a lower in
after HIFU ablation, a slightly high intensity signal appeared in the left
and T2WI. (G) The MRS after HIFU shows a similar pattern to that be
changes in amplitude; the lipid resonance at 1.3 ppm increased, an
section shows lysed membranes, poorly delineated cells, pycnotic
cytoplasm after HIFU ablation.Increased Cho Resonance andCho/Lip Ratio of Liver VX2Tumor
The rabbit VX2 tumor mass grows in the left or middle lobe of the
liver 2 weeks after implantation, lesions appeared as slightly low intense
nodules on T1WI (Figure 2, A and I ) and hyperintense signal on
T2WI (Figure 2, B and J ). The Cho peak at 3.2 ppm was significantly
increased to 3.16 ± 0.58, and the Cho/Lip ratio was significantly
increased to 0.22 ± 0.03 in liver VX2 tumor in comparison with normal
liver, P b .001 (Figures 1C, 2, C and K, and 3).
Decreased Cho Resonance and Cho/Lip Ratio of Liver VX2
Tumor after HIFU Ablation
Tumor lesion shows a slightly low intensity signal on T1WI and a
slightly hyperintense signal on T2WI in both groups after complete
HIFU ablation (Figure 2, E and F ) and the partial HIFU ablation
(Figure 2,M and N ). The signals on T1WI did not show any changes
after HIFU ablation in both groups (Figure 2, A, E and I, M ). The
signals on T2WI were decreased after HIFU ablation in both groups
relative to those before ablation (Figure 2, B, F and J, N ); however, the
intensities of signal on T2WI after complete HIFU ablation did not show
an obvious difference from those after partial HIFU ablation (Figure 2, F
and N ). The MRS after complete HIFU ablation shows a significant
decrease of Cho resonance at 3.2 ppm to the level of normal liver after
ablation; the amplitude of the lipid resonance at 1.3 ppm increased, and
the Cho/Lip ratio decreased to 0.02 ± 0.00 (Figures 1G, 2G, and 3), P b
.001. H&E staining shows complete coagulative necrosis with poorly
delineated cells, lysed membranes, pycnotic nuclei, and nuclear
fragmentation after complete HIFU ablation; viable tumor cells cannot
be observed (Figure 2H ). The intact tumor cells were shown before
HIFU ablation (Figure 2, D and L). After partial HIFU ablation, the
MRS shows a significant reduction ofCho resonance (Figure 2O), but the
amplitude is still higher than normal liver or tumor after complete
ablation (Figures 1G and 2G ), P b .001; the Cho/Lip ratio of partial
ablation was lower than that of complete ablation, P b .001 (Figure 3).tion. (A) T1WI of normal liver shows no mass in the left lobe of the
r. (C) MRS of normal liver shows that the Cho peak appeared at 3.2
o is 0.03 ± 0.00. (D) The H&E-stained section shows normal liver
tensity signal appeared in the left lobe of normal liver. (F) On T2WI
lobe of normal liver. The arrows indicate the ablated region on T1WI
fore HIFU, and the Cho resonance is at 3.2 ppm with no significant
d the Cho/Lip ratio after HIFU is 0.02 ± 0.00. (H) The H&E-stained
nuclei, nuclear fragmentation, and heavy staining of hepatocyte
Figure 2. The MRI and MRS of liver VX2 tumor before and after complete and partial HIFU ablation. (A and I) Lesions of rabbit VX2 tumor
were visible in the middle lobe of the liver 2 weeks after implantation, lesions appeared as slightly low intense nodules on T1WI images.
(B and J) On T2WI, the lesions appeared hyperintense signals. (C and K) The Cho peak at 3.2 ppm is significantly increased in liver VX2
tumor (3.16 ± 0.58), and the Cho/Lip ratio is 0.22 ± 0.03. (D and L) The H&E-stained sections show untreated VX2 liver before HIFU. (E) On
T1WI after complete HIFU ablation, the lesion shows a slightly low intensity signal. (F) On T2WI after complete HIFU ablation, the lesion
shows a slightly hyperintense signal. (G) TheMRS after complete HIFU ablation shows a significant decrease in Cho resonance at 3.2 ppm
with no significant changes in amplitude; the amplitude of the lipid resonance at 1.3 ppm increased, and the Cho/Lip ratio after HIFU is
0.02 ± 0.00. (H) The H&E-stained section shows poorly delineated cells, lysed membranes, pycnotic nuclei, and nuclear fragmentation
after complete HIFU ablation; viable tumor cells cannot be observed. (M) On T1WI after partial HIFU ablation, the lesion shows a slightly
low intensity signal. (N) On T2WI after partial HIFU ablation, the lesion shows a slightly hyperintense signal. (O) TheMRS after partial HIFU
ablation shows a reduction in Cho resonance, but the amplitude is still higher than normal liver or tumor after complete ablation. (P) The
H&E-stained section shows coagulative necrosis in the region of ablation, but viable tumor cells can be found adjacent to the necrosis.
The arrows indicate the tumor mass on T1WI and T2WI.
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tumor cells can be found adjacent to the necrosis (Figure 2P).
Discussion
HIFU has been applied to ablate solid malignant tumor with a
well-defined volume. It has the advantages of non-invasion,
non-ionization, and fewer complications after treatment in compar-
ison to conventional surgery, radiotherapy, and chemotherapy.
However, tumor relapse due to incomplete ablation still remains a
clinical challenge that calls for the imaging modalities to identify the
completeness of tumor necrosis. Recently, MRI or US is generally
used to guide and monitor HIFU ablation, and guidance of HIFU by
US in China is preferable, because of its low cost. During the HIFU
ablation procedure, hyperechoic changes on grayscale ultrasound
images obtained after each exposure are used to evaluate the extent of
the area ablated on each slice [10–13]. However, the appearance ofhyperechoic changes does not always mean complete tumor necrosis
[14–17]. In addition, conventional MRI and contrast-enhanced (CE)
MRI were used to evaluate the changes of tumor size and signal
intensity and also to detect the tumor necrosis in primary hepatic
carcinoma after HIFU ablation for follow-up [18]. However, CE
MRI has been unsuccessful to early detect tumor residual so far, due
to the similar nonspecific contrast enhancement in the periphery area
of the ablation, which may confuse residual tumor with benign
peri-ablational hyperemic tissue or reactive granulation tissue because
of increased capillary permeability and therefore increase the passive
distribution of contrast reagents [19,20]. Likewise, the hepatic
carcinoma reoccurrences were detected at the margin of the treated
lesions 3 months after HIFU ablation due to cancer residual, which
means CE MRI failed to detect the tumor residual early after HIFU
ablation [18]. The recent detection of tumor residual and relapse
depends on long-term periodical follow-up with MRI after treatment,
Figure 3. Comparison of Cho, Lip, and Cho/Lip ratio in normal liver and liver VX2 tumor before and after HIFU ablation. (A) Cho value in
non-tumor, tumor complete HIFU, and tumor partial HIFU groups before and after HIFU ablation. (B) Lip value in non-tumor, tumor
complete HIFU, and tumor partial HIFU groups before and after HIFU ablation. (C) Cho/Lip ratio in non-tumor, tumor complete HIFU, and
tumor partial HIFU groups before and after HIFU ablation. ***P b .001, **P b .01, and *P b .05.
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Therefore, it is necessary to early evaluate the adequacy of tumor
lesion necrosis after HIFU ablation with another imaging modality.
We tried to access the completeness of liver tumor necrosis early after
HIFU ablation from a functional perspective. Therefore, we
introduced MRS into the assessment of HIFU ablation on liver
tumor to see whether MRS can show the difference of the metabolites
in tumors after complete and partial HIFU ablation.
MRS is an analytical method that is used to identify and quantify
the metabolites in human tissues. It differs from conventional MRI in
that the spectra provide physiological and chemical information
instead of anatomy. MRS has been used for cancer diagnosis,
treatment monitoring, and patient follow-up [6,21].
The Cho peak is assigned at 3.2 ppm and represents the sum of
Cho and Cho-containing compounds (e.g., Cho, phosphocholine,
and glycerophosphocholine). Cho is a marker for cellular membrane
turnover (phospholipid synthesis and degradation) that reflects
cell-membrane metabolism. Its increase has been attributed to
increased biosynthesis of membrane phospholipids and therefore
cellular proliferation. Abnormal levels of Cho compounds were
typically found in more active tumor masses [22]. Viable tumors
consist of rapidly proliferating cells, causing a high Cho peak, whereas
necrotic tumors have decreased cellularity, causing the Cho peak to
diminish. Lipid compounds peak at 0.9 to 1.4 ppm that represent cell
necrosis or membrane breakdown that may precede necrosis. In
in vivo proton MRS, the evaluation of Cho levels was used to
differentiate benign and malignant tumors [23].
In this study, we investigated the characterization of MRS before
and early after HIFU treatment in VX2 liver cancer tissue and normal
liver. Normal liver did not show any significant difference of Cho
peak after HIFU treatment; however, the lipid peak increased, which
resulted from liver necrosis, and the Cho/Lip ratio of normal liver
after HIFU was significantly decreased in comparison to that in
normal liver. The Cho of VX2 liver cancer tissue was significantly
higher than that of normal livers, which is consistent with the
previous study [6], and the Cho significantly decreased in both
complete ablation group and partial ablation group after treatment.
The Cho in complete ablation group did not show any difference
with normal liver; however, the Cho in the partial ablation group was
higher than that in normal liver before or after HIFU treatment due
to the residual part of tumors, which was confirmed by pathologicexaminations. The Cho and Cho/Lip values show a significant
difference between partial ablation group and complete ablation
group after HIFU treatment, so MRS may have the potential to
distinguish residual portions of liver tumor from necrosis and perform
additional HIFU ablation on residual portions, for future clinical
monitoring of HIFU ablation, and the Cho and Cho/Lip of normal
liver tissue close to the lesion can be used as a self-reference.
In conclusion, MRS may be used as a complement to conventional
MRI after HIFU treatment to provide some information about the
biochemical changes for immediately identifying the tissue coagula-
tion and tumor residual during MRI-guided HIFU treatment or early
evaluation of HIFU treatment.
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